tetano
Editor, Senior Moderator
J Med Virol
. 2022 Jun 2.
doi: 10.1002/jmv.27911. Online ahead of print.
Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: a prospective observational study
Eun-Hee Nah[SUP] 1 [/SUP], Seon Cho[SUP] 1 [/SUP], Hyeran Park[SUP] 1 [/SUP], Suyoung Kim[SUP] 1 [/SUP], Dongwon Noh[SUP] 1 [/SUP], Eunjoo Kwon[SUP] 1 [/SUP], Han-Ik Cho[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Assaying of anti-spike-protein receptor-binding domain (S-RBD) antibodies is used to aid evaluations of the immune statuses of individuals. The aim of this study was to determine the antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines and to identify the factors affecting this response among healthcare workers (HCWs) at health promotion centers.
Methods: In this prospective observational study, 1,095 consenting HCWs were recruited from 16 health checkup centers and were tested at T0 (day of first dose), T1-1 (1 month after first dose), T2-0 (day of second dose), T2-1 (1 month after second dose) and T2-3 (3 months after second dose). SARS-CoV-2 antibodies were measured using a chemiluminescence microparticle immunoassay with SARS-CoV-2 IgG II Quant in the ARCHITECT system (Abbott Diagnostics).
Results: At T1-1, anti-SARS-CoV-2 S-RBD IgG levels were significantly higher in participants who received mRNA vaccines than in those who received viral vector vaccines (P<0.001). At T2-1, anti-SARS-CoV-2 S-RBD IgG levels were about 10 times higher than at T1-1 in participants who received homologous mRNA vaccines, which decreased to a third of those at T2-3. Anti-SARS-CoV-2 S-RBD IgG levels were highest among those who received homologous mRNA vaccines, followed by heterologous mRNA viral vector vaccines and homologous viral vector vaccines at T2-3 (P<0.001). In a multivariable linear regression analysis, being female, taking at least one mRNA vaccine, and having a history of recovery from COVID-19 were significantly associated with anti-S-RBD levels.
Conclusion: Anti-SARS-CoV-2 S-RBD IgG levels were decreased at 3 months after two-dose vaccinations and were associated with sex, vaccine type, and COVID-19 history. This article is protected by copyright. All rights reserved.
Keywords: SARS-CoV-2 IgG; anti-spike-protein receptor-binding domain (S-RBD) antibodies; healthcare workers; mRNA vaccines; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines; viral vector vaccines.
. 2022 Jun 2.
doi: 10.1002/jmv.27911. Online ahead of print.
Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: a prospective observational study
Eun-Hee Nah[SUP] 1 [/SUP], Seon Cho[SUP] 1 [/SUP], Hyeran Park[SUP] 1 [/SUP], Suyoung Kim[SUP] 1 [/SUP], Dongwon Noh[SUP] 1 [/SUP], Eunjoo Kwon[SUP] 1 [/SUP], Han-Ik Cho[SUP] 2 [/SUP]
Affiliations
- PMID: 35655438
- DOI: 10.1002/jmv.27911
Abstract
Background: Assaying of anti-spike-protein receptor-binding domain (S-RBD) antibodies is used to aid evaluations of the immune statuses of individuals. The aim of this study was to determine the antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines and to identify the factors affecting this response among healthcare workers (HCWs) at health promotion centers.
Methods: In this prospective observational study, 1,095 consenting HCWs were recruited from 16 health checkup centers and were tested at T0 (day of first dose), T1-1 (1 month after first dose), T2-0 (day of second dose), T2-1 (1 month after second dose) and T2-3 (3 months after second dose). SARS-CoV-2 antibodies were measured using a chemiluminescence microparticle immunoassay with SARS-CoV-2 IgG II Quant in the ARCHITECT system (Abbott Diagnostics).
Results: At T1-1, anti-SARS-CoV-2 S-RBD IgG levels were significantly higher in participants who received mRNA vaccines than in those who received viral vector vaccines (P<0.001). At T2-1, anti-SARS-CoV-2 S-RBD IgG levels were about 10 times higher than at T1-1 in participants who received homologous mRNA vaccines, which decreased to a third of those at T2-3. Anti-SARS-CoV-2 S-RBD IgG levels were highest among those who received homologous mRNA vaccines, followed by heterologous mRNA viral vector vaccines and homologous viral vector vaccines at T2-3 (P<0.001). In a multivariable linear regression analysis, being female, taking at least one mRNA vaccine, and having a history of recovery from COVID-19 were significantly associated with anti-S-RBD levels.
Conclusion: Anti-SARS-CoV-2 S-RBD IgG levels were decreased at 3 months after two-dose vaccinations and were associated with sex, vaccine type, and COVID-19 history. This article is protected by copyright. All rights reserved.
Keywords: SARS-CoV-2 IgG; anti-spike-protein receptor-binding domain (S-RBD) antibodies; healthcare workers; mRNA vaccines; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines; viral vector vaccines.